SCHEMBL753288

SCHEMBL753288

CC(C)(C)Nc1ccc(C(=O)O)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
RARB P10826 5/20 0.45
RARA P10276 4/20 0.45
RARG P13631 2/20 0.45
ABCC9 O60706 1/20 0.44
ABCC8 Q09428 1/20 0.44
KCNJ11 Q14654 1/20 0.44
KCNJ8 Q15842 1/20 0.44
HTT P42858 1/20 0.39
SLC22A12 Q96S37 2/20 0.39
PTGFR P43088 1/20 0.38
HDAC1 Q13547 2/20 0.38
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 2/20 0.38
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407352 0.87 EPHX2 (0.44) EPHX2NR1H4RARBRARARARG
SCHEMBL22855238 0.83 KDM4E (0.43) ABCC9ABCC8KCNJ11KCNJ8MEN1
SCHEMBL18309782 0.83 GAA (0.50) EPHX2NR1H4ABCC9ABCC8KCNJ11
SCHEMBL24965982 0.83 EPHX2 (0.41) EPHX2NR1H4RARBRARARARG
SCHEMBL22504471 0.81 KMT2A (0.53) SLC22A12MEN1USP2ALDH1A1HPGD
SCHEMBL2432970 0.80 RARB (0.48) EPHX2NR1H4RARBRARARARG
SCHEMBL13610858 0.79 SMN1; SMN2 (0.52) NR1H4HTTMEN1ALDH1A1HPGD
SCHEMBL8829073 0.79 RARB (0.46) EPHX2NR1H4RARBRARARARG
SCHEMBL18832261 0.78 EPHX2 (0.41) EPHX2NR1H4RARBRARARARG
SCHEMBL18856971 0.78 EPHX2 (0.41) EPHX2NR1H4RARBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996563-B1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2012-03-21 EP disclosed